Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Change in mammographic density across birth cohorts of Dutch breast cancer screening participants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Vitamin D levels and Cancer Incidence in 217.244 individuals from Primary Health Care in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Human papillomavirus and p16 in squamous cell carcinoma and intraepithelial neoplasia of the vagina

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Intra- and inter-laboratory agreement of the FAM19A4/mir124-2 methylation test: Results from an international study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Inverted papilloma of the conjunctiva

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Frederique J Vink
  • Chris J L M Meijer
  • Gary M Clifford
  • Mario Poljak
  • Anja Oštrbenk
  • Karl Ulrich Petry
  • Beate Rothe
  • Jesper Bonde
  • Helle Pedersen
  • Silvia de Sanjosé
  • Montserrat Torres
  • Marta Del Pino
  • Wim G V Quint
  • Kate Cuschieri
  • Elia Alcañiz Boada
  • Nienke E van Trommel
  • Birgit I Lissenberg-Witte
  • Arno N Floore
  • Albertus T Hesselink
  • Renske D M Steenbergen
  • Maaike C G Bleeker
  • Daniëlle A M Heideman
Vis graf over relationer

Widespread adoption of primary human papillomavirus (HPV)-based screening has encouraged the search for a triage test which retains high sensitivity for the detection of cervical cancer and precancer, but increases specificity to avoid overtreatment. Methylation analysis of FAM19A4 and miR124-2 genes has shown promise for the triage of high-risk (hr) HPV-positive women. In our study, we assessed the consistency of FAM19A4/miR124-2 methylation analysis in the detection of cervical cancer in a series of 519 invasive cervical carcinomas (n = 314 cervical scrapes, n = 205 tissue specimens) from over 25 countries, using a quantitative methylation-specific PCR (qMSP)-based assay (QIAsure Methylation Test®). Positivity rates stratified per histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region were calculated. In total, 510 of the 519 cervical carcinomas (98.3%; 95% CI: 96.7–99.2) tested FAM19A4/miR124-2 methylation-positive. Test positivity was consistent across the different subgroups based on cervical cancer histotype, FIGO stage, hrHPV status, hrHPV genotype, sample type and geographical region. In conclusion, FAM19A4/miR124-2 methylation analysis detects nearly all cervical carcinomas, including rare histotypes and hrHPV-negative carcinomas. These results indicate that a negative FAM19A4/miR124-2 methylation assay result is likely to rule out the presence of cervical cancer.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
ISSN0020-7136
DOI
StatusE-pub ahead of print - 7 aug. 2019

ID: 57728908